In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Getting ready for a Java interview in 2025? It can feel like a lot, especially with so many different things to know. Whether you’re just starting out or you’ve been coding for a while, this guide is ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

President Donald Trump knocked what he called a "stupid question" from ABC News' Terry Moran about his confidence in Secretary of Defense Pete Hegseth. During a sit-down primetime interview marking ...

These days, Jeff Bezos might spend more time planning his lavish Venetian wedding than hiring frontline engineers and executives. But back in the day when he was actively leading Amazon, Bezos always ...